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Malaria causes great suffering with estimated annual mortalities of over 800.000 people, principally in Africa 
and Asia. A major problem in the fight against malaria is resistance to current drug treatments and several 
strategies have been employed to combat this problem. Beside these, inhibitors of the newly validated target 
dihydroorotate dehydrogenase (DHODH) could play an important role as future single or combinatory 
treatment of malaria. A continuing program of ours investigates Plasmodium Falciparum dihydroorotate 
dehydrogenase (pfDHODH) inhibitors based on N-substituted salicylamides scaffold.1 Recently, the most 
active model of the series (1) showed low micromolar range activity over pfDHODH together with a quite 
interesting selectivity over human DHODH (hDHODH).1 
Isosteric replacement is a widely used approach within Medicinal Chemistry for improving properties of a 
lead compound such as bioavailability, selectivity, and potency.2 Since 2006, the Med Chem group at DSTF 
directed its efforts towards the investigation of hydroxylated pentatomic heterocyclic systems in order to 
create a sophisticate tool able to iso/bioisosterically mimic the carboxylic group, both electronically and 
sterically.3 More recently, attentions were directed in the application of this technology to other acidic 
systems.4  
In this poster, the salicylamide moiety of highly selective pfDHODH where identified as a possible occasion 
for a bioisosteric modulation. The synthesis, the dissociation constant (pKa) as well as the preliminary 
pfDHODH in vitro inhibition assays are presented and discussed. 
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